PIN1抗体—艾普蒂

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane: Mouse brain tissue, Primary antibody: P08623(PIN1 Antibody) at dilution 1/300, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P08623(PIN1 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain tissue using P08623(PIN1 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

PIN1 (Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1) is a unique enzyme belonging to the parvulin family of prolyl isomerases. It specifically catalyzes the cis-trans isomerization of phosphorylated serine/threonine-proline (pSer/Thr-Pro) motifs in target proteins, modulating their conformation, stability, and activity. PIN1 plays critical roles in regulating cell cycle progression, gene transcription, DNA damage response, and apoptosis. Its dysregulation is implicated in various diseases, including cancer, Alzheimer’s disease, and immune disorders. In cancer, PIN1 is often overexpressed and promotes oncogenic signaling by stabilizing activated kinases (e.g., β-catenin, cyclin D1) or inactivating tumor suppressors (e.g., p53). Conversely, in Alzheimer’s, PIN1 dysfunction correlates with hyperphosphorylated tau aggregation and neurodegeneration.

PIN1 antibodies are essential tools for detecting PIN1 expression and studying its biological functions. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to assess PIN1 levels, subcellular localization, and interactions in tissues or cultured cells. Specific monoclonal or polyclonal antibodies help researchers explore PIN1's role in disease mechanisms, therapeutic targeting, and biomarker discovery. Validated PIN1 antibodies are critical for ensuring specificity in experimental models, particularly given PIN1's structural complexity and post-translational modifications. Ongoing research continues to highlight PIN1 as a promising therapeutic target, driving demand for reliable antibodies in both basic and translational studies.